Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

VRCA Account Payables

Amounts the company owes suppliers for goods and services received.

Verrica Pharmaceuticals Inc.NASDAQ: VRCA

Account Payables · Q1 FY2026 · quarter ended Mar 2026

Account payables rises 52.0% from a year ago

Account payables stood at $2.19M at the end of Q1 FY2026, up 52.0% from a year earlier and up 5.8% from the prior quarter. Over 3 fiscal years it compounded at +59.9% a year.

Context

  • Account payables amounted to 5.7% of total assets at the end of Q1 FY2026, up 2.2 pp from a year earlier.
  • Account payables increased in 2 of the last 3 fiscal years.

What to watch

Whether account payables keeps rising in the next quarterly balance sheet after a +52.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.19M+5.8% QoQ
Last fiscal yearDec 2025
$2.07M+9.3% YoY
Year agoMar 2025
$1.44M+52.0% since
Account Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+52.0%——
1 year+9.3%——
3-year CAGR+59.9%——
5-year CAGR——
10-year CAGR——

Account Payables history

USD · from the balance sheet

Latest · FY2025
2.07M USD
Year-over-year change
+9.3%
4-year CAGR
+25.1%

Account Payables vs competitors

How VRCA compares with its peers on the latest reported figures

  • VRCA's Mar 2026 account payables of $2.19M is the 3rd highest of the 5 companies compared; the peer median is $2.33M.
  • Its year-over-year change of +52.0% is the highest of 5, against a peer median of +16.1%.
  • Account payables amounts to 5.7% of total assets for VRCA, versus a peer median of 1.5%.
VRCA Competitors Peer median
Account Payables for VRCA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SABSSAB Biotherapeutics, Inc.Jun 2026$3.86M +47.0%-5.1%1.6%
ANTXAN2 Therapeutics, Inc.Mar 2026$2.62M -14.9%+12.5%3.0%
VRCAVerrica Pharmaceuticals Inc.Mar 2026$2.19M +52.0%+59.9%5.7%
BOLDBoundless Bio, Inc.Mar 2026$2.04M +49.0%+2.1%1.4%
QTTBQ32 Bio Inc.Mar 2026$653K -75.9%-15.1%1.0%
Peer median (excluding VRCA) $2.33M+16.1%-1.5%1.5%

Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents15.75M34.27M69.55M46.33M30.15M
Short-term Investments54.6M0000
Net Receivables0487K4.42M77K5.4M
Inventory001.02M2.46M2.24M
Other Current Assets04.36M2.55M2.31M4.76M
Total Current Assets74.33M39.12M77.53M51.18M42.54M
Property, Plant & Equipment (Net)5.5M5.33M3.62M2.58M1.86M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets295K276K452K376K2.73M
Total Non-current Assets5.8M5.61M4.07M2.96M4.59M
Total Assets80.13M44.72M81.6M54.13M47.13M
Account Payables845K507K2.46M1.9M2.07M
Short-term Debt41.69M0012.94M0
Tax Payables00000
Deferred Revenue0000782K
Other Current Liabilities1.67M1.4M9.04M11.59M10.44M
Total Current Liabilities46.06M3.46M17.02M29.01M16.44M
Long-term Debt0042.87M30.98M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0002.65M5.07M
Total Non-current Liabilities1.47M1.23M44.81M34.98M5.95M
Total Liabilities47.52M4.69M61.83M63.99M22.39M
Common Stock3K4K4K9K2K
Retained Earnings(138.97M)(163.45M)(230.45M)(307.03M)(324.91M)
Accumulated OCI(29K)0000
Other Stockholders Equity00000
Minority Interest00000
Total Equity32.61M40.03M19.76M(9.86M)24.74M
Total Debt43.41M1.53M45.51M45.94M1.63M
Net Debt27.66M(32.75M)(24.04M)(390K)(28.52M)

Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Intrinsic Alpha fair value

Locked

Current Price

$3.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.